ValuEngine cut shares of iCAD (NASDAQ:ICAD) from a sell rating to a strong sell rating in a research note released on Tuesday morning.
Shares of iCAD (ICAD) opened at $3.42 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.67 and a debt-to-equity ratio of 0.31. iCAD has a fifty-two week low of $2.93 and a fifty-two week high of $6.07. The stock has a market cap of $60.43, a PE ratio of -4.22 and a beta of 1.32.
Hedge funds have recently added to or reduced their stakes in the business. Segall Bryant & Hamill LLC bought a new stake in iCAD during the third quarter valued at about $133,000. Dimensional Fund Advisors LP boosted its holdings in iCAD by 165.1% during the third quarter. Dimensional Fund Advisors LP now owns 89,043 shares of the technology company’s stock valued at $394,000 after acquiring an additional 55,455 shares during the period. Fairpointe Capital LLC bought a new stake in iCAD during the fourth quarter valued at about $1,621,000. Finally, Vanguard Group Inc. boosted its holdings in iCAD by 0.4% during the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock valued at $1,912,000 after acquiring an additional 2,007 shares during the period. Institutional investors own 21.09% of the company’s stock.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.